Aceto Strengthens Self-Manufacturing and Vaccine and Biopharmaceutical Offering With Acquisition of A&C
With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.\n\xe2\x80\x9cWith the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,\xe2\x80\x9d said Gilles Cottier, Chief Executive Officer of Aceto.
Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced today its acquisition of A&C, a global GMP (Good Manufacturing Practices) manufacturer of specialty excipients, buffers, and process solutions. The acquisition helps to drive Aceto’s growth strategy, increasing the company’s GMP manufacturing, packaging, and ingredients offerings for the cell culture, vaccine, and biopharmaceutical industries, while also expanding its North American footprint.
A&C solves customers' technical, product and regulatory challenges through GMP custom ingredient development, manufacturing, and packaging in the life science sector. With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.
“With the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,” said Gilles Cottier, Chief Executive Officer of Aceto. “Across all of our recent acquisitions, including Syntor and IsleChem, Aceto can now offer customers an extensive selection of highest quality and competitively priced products and services to help customers secure and optimize critical supply as well as bring new products to market globally.”
“A&C is a service-driven organization with a mission of finding unique solutions to customers’ GMP challenges and supporting them through all stages of the development cycle,” said Ken McCracken, President & CEO of A&C. “This fundamental approach to our business perfectly aligns with Aceto’s value proposition and customer-centric service philosophy. We are excited to provide customers a differentiated, integrated suite of product offerings.”
Aceto will continue to support A&C’s manufacturing facilities and offices in the USA, Canada, and Ireland. Financial terms were not disclosed.
For more information, please visit Aceto.com.
About Aceto
Founded in 1947, Aceto is a leading global provider of differentiated specialty materials in life sciences and advanced technology end markets. With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries. Aceto’s global operations, including a significant staff on the ground in China, India, Europe and North America, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities. www.aceto.com
About A&C
A&C is a global GMP manufacturer of excipients, buffers, process solutions and a select number of active pharmaceutical ingredients (APIs). A&C has been servicing the global life sciences industry since 1966 and has offices and GMP production facilities in North America and Europe. A&C is committed to providing certified GMP products in full compliance with international regulatory requirements to meet customers’ needs globally.
www.acggp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005342/en/